502 related articles for article (PubMed ID: 14691461)
1. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice.
Tilli MT; Reiter R; Oh AS; Henke RT; McDonnell K; Gallicano GI; Furth PA; Riegel AT
Mol Endocrinol; 2005 Mar; 19(3):644-56. PubMed ID: 15550471
[TBL] [Abstract][Full Text] [Related]
3. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
[TBL] [Abstract][Full Text] [Related]
4. An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer.
Reiter R; Wellstein A; Riegel AT
J Biol Chem; 2001 Oct; 276(43):39736-41. PubMed ID: 11502741
[TBL] [Abstract][Full Text] [Related]
5. Endogenously expressed estrogen receptor and coactivator AIB1 interact in MCF-7 human breast cancer cells.
Tikkanen MK; Carter DJ; Harris AM; Le HM; Azorsa DO; Meltzer PS; Murdoch FE
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12536-40. PubMed ID: 11050174
[TBL] [Abstract][Full Text] [Related]
6. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
8. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
[TBL] [Abstract][Full Text] [Related]
9. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
[TBL] [Abstract][Full Text] [Related]
10. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.
Anzick SL; Kononen J; Walker RL; Azorsa DO; Tanner MM; Guan XY; Sauter G; Kallioniemi OP; Trent JM; Meltzer PS
Science; 1997 Aug; 277(5328):965-8. PubMed ID: 9252329
[TBL] [Abstract][Full Text] [Related]
11. Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor.
Landry M; Di Paolo T
Brain Res Mol Brain Res; 2003 Apr; 112(1-2):82-9. PubMed ID: 12670705
[TBL] [Abstract][Full Text] [Related]
12. Association of steroid receptor coactivator AIB1 with estrogen receptor-alpha in breast cancer cells.
Azorsa DO; Cunliffe HE; Meltzer PS
Breast Cancer Res Treat; 2001 Nov; 70(2):89-101. PubMed ID: 11768608
[TBL] [Abstract][Full Text] [Related]
13. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
[TBL] [Abstract][Full Text] [Related]
14. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
16. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance.
Louie MC; Zou JX; Rabinovich A; Chen HW
Mol Cell Biol; 2004 Jun; 24(12):5157-71. PubMed ID: 15169882
[TBL] [Abstract][Full Text] [Related]
17. Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.
Glaeser M; Niederacher D; Djahansouzi S; Hanstein B; Dittrich R; Beckmann MW; Fasching PA; Ackermann S
Anticancer Res; 2006; 26(1B):735-44. PubMed ID: 16739346
[TBL] [Abstract][Full Text] [Related]
18. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.
Tee MK; Rogatsky I; Tzagarakis-Foster C; Cvoro A; An J; Christy RJ; Yamamoto KR; Leitman DC
Mol Biol Cell; 2004 Mar; 15(3):1262-72. PubMed ID: 14699072
[TBL] [Abstract][Full Text] [Related]
19. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
Power KA; Thompson LU
Breast Cancer Res Treat; 2003 Oct; 81(3):209-21. PubMed ID: 14620916
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants for the tissue specificity of SERMs.
Shang Y; Brown M
Science; 2002 Mar; 295(5564):2465-8. PubMed ID: 11923541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
